Poly(2-allylamidopropyl-2-oxazoline)-Based Hydrogels: From Accelerated Gelation Kinetics to <i>In Vivo</i> Compatibility in a Murine Subdermal Implant Model

نویسندگان

چکیده

A rapid photo-curing system based on poly(2-ethyl-2-oxazoline-co-2-allylamidopropyl-2-oxazoline) and its in vivo compatibility are presented. The base polymer was synthesized from the copolymerization of 2-ethyl-2-oxazoline (EtOx) methyl ester containing 2-methoxycarboxypropyl-2-oxazoline (C3MestOx) followed by amidation with allylamine to yield a highly water-soluble macromer. We showed that spherical hydrogels can be obtained simple water-in-oil gelation method using thiol–ene coupling investigated biocompatibility these hydrogel spheres 28-day murine subdermal model. For comparison, prepared poly(ethylene glycol) were also implanted. Both materials displayed mild, yet typical foreign body responses little signs fibrosis. This is first report response poly(2-oxazoline) hydrogel, which paves way for future investigations into how this tailorable class used implantable devices.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Study In Vivo Intraocular Biocompatibility of In Situ Gelation Hydrogels: Poly(2-Ethyl Oxazoline)-Block-Poly(ε-Caprolactone)-Block-Poly(2-Ethyl Oxazoline) Copolymer, Matrigel and Pluronic F127

The long term in vivo biocompatibility is an essential feature for the design and development of sustained drug release carriers. In the recent intraocular drug delivery studies, hydrogels were suggested as sustained release carriers. The biocompatibility test for these hydrogels, however, was commonly performed only through in vitro cell culture examination, which is insufficient before the cl...

متن کامل

Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant

STUDY QUESTION Is it possible to extend the use of the 3-year one-rod etonogestrel (ENG)-releasing subdermal contraceptive implant to 5 years? SUMMARY ANSWER The extended use of the one-rod ENG-releasing subdermal contraceptive implant showed 100% efficacy in years 4 and 5. WHAT IS KNOWN ALREADY The initial regulated trials on the ENG-releasing subdermal contraceptive implant conducted in t...

متن کامل

Teaching NeuroImages: Ulnar neuropathy related to a contraceptive subdermal implant.

A 51-year-old woman experienced intermittent left hand numbness and weakness over 2 years, with a claw-hand deformity and weakness of finger abduction, adduction, and distal interphalangeal joint flexion of the medial 2 fingers. Wrist flexion produced hand radial deviation. Palmar and dorsal aspects of digits IV (medially) and V, including medial forearm, had decreased pinprick sensation. Nerve...

متن کامل

from linguistics to literature: a linguistic approach to the study of linguistic deviations in the turkish divan of shahriar

chapter i provides an overview of structural linguistics and touches upon the saussurean dichotomies with the final goal of exploring their relevance to the stylistic studies of literature. to provide evidence for the singificance of the study, chapter ii deals with the controversial issue of linguistics and literature, and presents opposing views which, at the same time, have been central to t...

15 صفحه اول

Comments on two subdermal implant articles.

I enjoyed reading the two articles written by Sam Rowlands in the October 2010 issue of the Journal. 1 2 They were comprehensive and gave valuable information to health care professionals providing a contraceptive subdermal implant service. There are, however, several points that require clarifi cation and/or correction. First, Norplant ® , the six-rod system, was manufactured by Leiras Oy, now...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Biomacromolecules

سال: 2021

ISSN: ['1525-7797', '1526-4602']

DOI: https://doi.org/10.1021/acs.biomac.1c00046